These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 2144560)
21. Quality of life in patients with Parkinson's disease who transfer from standard levodopa to Sinemet CR: the STAR Study. The STAR Multicenter Study Group. Grandas F; Martínez-Martín P; Linazasoro G J Neurol; 1998 May; 245 Suppl 1():S31-3. PubMed ID: 9617721 [TBL] [Abstract][Full Text] [Related]
22. An open multicenter trial of Sinemet CR in levodopa-naive Parkinson's disease patients. Olanow CW; Nakano K; Nausieda P; Tetrud JA; Manyam B; Last B; Block G; Liss C; Bush D Clin Neuropharmacol; 1991 Jun; 14(3):235-40. PubMed ID: 2070363 [TBL] [Abstract][Full Text] [Related]
23. Controlled-release carbidopa/levodopa in the treatment of Parkinsonism. Hutton JT; Dippel RL; Bianchine JR; Strahlendorf HK; Meyer PG Clin Neuropharmacol; 1984; 7(2):135-9. PubMed ID: 6375861 [TBL] [Abstract][Full Text] [Related]
24. New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings. Neurology; 1989 Nov; 39(11 Suppl 2):1-106. PubMed ID: 2586761 [No Abstract] [Full Text] [Related]
26. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa. Aarli JA; Gilhus NE Neurology; 1989 Nov; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767 [TBL] [Abstract][Full Text] [Related]
27. Sinemet CR for Parkinson's disease. Med Lett Drugs Ther; 1991 Oct; 33(854):92-3. PubMed ID: 1895993 [No Abstract] [Full Text] [Related]
28. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. Fung VS; Herawati L; Wan Y; ; Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551 [TBL] [Abstract][Full Text] [Related]
29. Treatment of early Parkinson's disease with controlled-release levodopa preparations. Rinne UK; Rinne JO Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766 [TBL] [Abstract][Full Text] [Related]
30. Necessity of long-term alertness in levodopa-carbidopa intestinal gel infusion for PD patients. Klostermann F; Bojarski C; Marzinzik F; Maier A; Schindlbeck KA; Ehlen F Mov Disord; 2017 Feb; 32(2):300-301. PubMed ID: 27859611 [No Abstract] [Full Text] [Related]
31. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa. Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700 [TBL] [Abstract][Full Text] [Related]
32. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa. Goetz CG; Tanner CM; Gilley DW; Klawans HL Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764 [TBL] [Abstract][Full Text] [Related]
33. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients. Libman I; Gawel MJ; Riopelle RJ; Bouchard S Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120 [TBL] [Abstract][Full Text] [Related]
36. Selegiline for Parkinson's disease. Calesnick B Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624 [TBL] [Abstract][Full Text] [Related]
37. Deprenyl (selegiline) in combination treatment of Parkinson's disease. Gerstenbrand F; Ransmayr G; Poewe W Acta Neurol Scand Suppl; 1983; 95():123-6. PubMed ID: 6428144 [TBL] [Abstract][Full Text] [Related]
38. [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution]. Amato L; Nava L; Rizzo M; Piccoli F Riv Neurol; 1985; 55(1):46-52. PubMed ID: 3927468 [No Abstract] [Full Text] [Related]
39. Istradefylline (Nourianz) for Parkinson's disease. Med Lett Drugs Ther; 2020 Feb; 62(1591):20-23. PubMed ID: 32022788 [No Abstract] [Full Text] [Related]